Navigation Links
Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
Date:3/17/2008

- Company on Track to Initiate Phase 2b in Second Quarter of 2008 -

- Conference Call Tomorrow at 8:00 a.m. Eastern Time -

SAN DIEGO, March 17 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive preliminary results from its ongoing Phase 2a proof-of-concept study of RDEA806, its novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV).

Preliminary results from the first two of three cohorts demonstrate that the oral dosing regimens tested so far produce robust reductions in plasma viral load and are well tolerated.

"These preliminary data, together with RDEA806's unique activity against resistant HIV in vitro and extensive safety experience, indicate that RDEA806 is a highly potent antiretroviral that warrants further study for both treatment-naive and treatment-experienced HIV patients," said Graeme Moyle, MBBS, MD, Director of HIV Research, Chelsea and Westminster Hospital, who is conducting the Phase 2a study and assisting with the design of the Phase 2b study.

Phase 2a Clinical Trial Design & Preliminary Results

The Phase 2a, randomized, double-blind, placebo-controlled trial is evaluating the antiviral activity, pharmacokinetics, safety and tolerability of RDEA806 versus placebo in 36 HIV-positive patients who are naive to antiretroviral treatment. Nine out of 12 patients in each of three cohorts will receive RDEA806. The primary efficacy endpoint is the change from baseline in plasma viral load. Preliminary results, which include those from the first ten evaluable patients in the 400mg twice daily cohort and the first eight evaluable patients in the 600mg once daily cohort, sh
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
2. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
10. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Global ENT ... to reach USD 23.01 million in 2022, according to ... base of geriatric population, increasing prevalence of ear, nose, ... of awareness among target customer base are expected serve ... forecast period. According to estimates published by the WHO, ...
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on ... financial results and provide a corporate update. Arena will ... Market closes that day. The conference call ... and 914.495.8552 for international callers. Please specify to the ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4
(Date:7/30/2015)... , ... July 30, 2015 ... ... a video, “Beachside Nursing Center,” to announce its position as one of ... Beachside's administrator and staff members support the CMS rating system, which monitors ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New ... Increases Training Capability , World renown body weight trainer, Paul Ziachik, announces ... that dramatically increases a person’s training capability. , The American College of Sports ...
(Date:7/30/2015)... ... 2015 , ... Boston Web Marketing is proud ... Partners is the platform for search marketing agencies to communicate with the Google ... to run successful search marketing campaigns. Google Partners also affords businesses the opportunity ...
(Date:7/30/2015)... ... 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers ... well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with ... from around the world. , “Like treatment of any other disease or condition, making ...
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of its ... to apply lotion or medication to a hard-to-reach area. This invention is patented. , ... to the back, and provides thorough coverage. The product would prevent the user from ...
Breaking Medicine News(10 mins):Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... 40 percent of new moms aren,t married, CDC reports ... of unmarried women having children has risen sharply in the ... officials. , In the United States, 40 percent of births ... to women in their 20s, not teenagers, according to a ...
... The beta-carotene in so-called "Golden Rice" converts to vitamin ... Medicine (www.bcm.edu) and Tufts University in an article that appears ... Clinical Nutrition . , Golden Rice was developed ... Foundation with the goal of creating rice that had beta-carotene ...
... Department Nurses for Role in Prestigious DesignationEMERYVILLE, Calif., ... of the nation,s largest providers of emergency department ... its client, Palomar Pomerado Health (PPH) system, has ... Center (ANCC). Only five percent of U.S. hospitals ...
... discussion about trade-offsSTANFORD, Calif., May 13 Americans ... involved in health care reform, according to new ... Longevity (SCL).The findings are the result of a ... and united the typically disconnected worlds of politics, ...
... Sharing Miracles, a 30-minute public affairs television program ... patients has expanded its reach across America, now airing ... The current episode features nine-time NBA all-star and Basketball ... year, the Sharing Miracles network has expanded ...
... ST. LOUIS, May 13 Express Scripts, Inc. (Nasdaq: ... Deutsche Bank 34th Annual Health Care Conference on May 19, ... Boston. This presentation will also be broadcast via the Internet ... Express Scripts web site at http://www.express-scripts.com . RealPlayer ...
Cached Medicine News:Health News:More Single Women Are Having Babies 2Health News:More Single Women Are Having Babies 3Health News:More Single Women Are Having Babies 4Health News:Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center 2Health News:Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center 3Health News:Stanford Center on Longevity Releases New Findings About Voter Attitudes on Health Care Reform 2Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 2Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 3Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 4Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 5Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 6Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 7
Contoured design provides secure support and immobilization of the wrist and distal forearm while preserving finger mobility...
Designed to provide comfortable support, protection and immobilization MCP joint along with immobilization of the wrist...
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: